CYTK Cytokinetics Inc - 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders.

The following is a brief description of each matter voted upon at the Company’s Annual Meeting of Stockholders on May 27, 2026 (the “Annual Meeting”), as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. Of the 124,237,822 shares of the Company’s common stock entitled to vote at the Annual Meeting, 116,125,730 shares of common stock, or 93.47%, of the total eligible votes to be cast, were represented at the Annual Meeting in person or by proxy, constituting a quorum. A more complete description of each matter is set forth in the Company’s definitive proxy statement for the Annual Meeting, which was filed with the Securities and Exchange Commission on April 17, 2026.

Proposal 1: Election of Three Class I Directors

The stockholders elected Edward M. Kaye, M.D., Wendell Wierenga, Ph.D., and Nancy J. Wysenski as Class I Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows:

Name

For

Withheld

Broker

Non-Vote

Edward M. Kaye, M.D.

104,633,356

3,234,862

8,257,512

Wendell Wierenga, Ph.D.

85,427,010

22,441,208

8,257,512

Nancy J. Wysenski

104,820,911

3,047,307

8,257,512

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of common stock

The stockholders approved the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan. The votes were as follows:

For

Against

Abstain

Broker Non-Vote

107,254,415

261,354

352,449

8,257,512

Proposal 3: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026

The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were as follows:

For

Against

Abstain

Broker Non-Vote

115,468,025

269,258

388,447

-0-

Proposal 4: Advisory Vote on Executive Compensation

The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2026 Annual Meeting of Stockholders. The votes were as follows:

For

Against

Abstain

Broker Non-Vote

104,005,531

3,018,095

844,592

8,257,512